OR (95% CI) | p values | |
---|---|---|
Dataset 1: all 290 patients | ||
Age (per year) | 1.13 (1.07 ~ 1.2) | p < 0.001*** |
Gender female (vs. male) | 1.43 (0.78–2.63) | 0.25 |
Genotypes | ||
COL1A1 or COL1A2 | Reference | – |
IFITM5 | 3.71 (1.13–12.25) | 0.029* |
WNT1 | 3.37 (1.06–10.69) | 0.037* |
All other AR genes | 3.16 (1.03–9.63) | 0.041* |
No mutation | 1.92 (0.43–7.91) | 0.37 |
Not tested | 1.33 (0.6–2.88) | 0.473 |
Drugs used | ||
Nevera | Reference | – |
Pamidronate | 3.78 (1.09–13.94) | 0.04* |
Zoledronate | 1.96 (0.59–7) | 0.285 |
BMD Z-scores (per SD) | 0.82 (0.7–0.95) | 0.011* |
Has LLD (vs. no LLD) | 1.07 (0.57–1.99) | 0.825 |
Dataset 2: the 145 COL1A1/2 patients only | ||
Age (per year) | 1.13 (1.05–1.22) | 0.001** |
Gender female (vs. male) | 1.81 (0.73–4.55) | 0.199 |
Genotype COL1A2b | 0.28 (0.1–0.71) | 0.01* |
Mutation-type qualitativec | 3.84 (1.34–12.52) | 0.017* |
BMD Z-scores (per SD) | 0.79 (0.61–0.99) | 0.048* |
Has LLD (vs. no LLD) | 0.57 (0.21–1.47) | 0.253 |